Overview
The purpose of this study is to explore pro-metastatic changes in breast cancer (BC) associated with the stiffness of biopsy site markers. This study aims to determine whether the stiffness of a biopsy site marker promotes inflammatory changes in breast cancer and to evaluate whether there is a relationship between biopsy site marker stiffness and inflammation.
Description
This prospective study aims to evaluate whether anti-inflammatory and pro-metastatic changes at the post-biopsy site are associated with the type of biopsy-site marker used, with particular focus on marker stiffness. Tissue samples will be collected from breast cancer patients who received a biopsy-site marker at the time of diagnosis.
Eligibility
Inclusion Criteria:
- Written informed consent (ICF) signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses.
- Female patients at \> 18 years of age at the time of signature of the ICF.
- Pathologically verified invasive breast cancer cases referred to OU for surgery.
Exclusion Criteria:
- Patients who had a biopsy at OUBI OKC.
- Patient who will undergo neoadjuvant therapy
- Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, uncontrolled diabetes mellitus, active bleeding diatheses, or active viral infection, including hepatitis B, hepatitis C, and human immunodeficiency virus. Screening for chronic conditions is not required.
- Currently pregnant or breastfeeding
- Patients not eligible for surgery
- Prisoners
